Search

Your search keyword '"Ducassou, A."' showing total 52 results

Search Constraints

Start Over You searched for: Author "Ducassou, A." Remove constraint Author: "Ducassou, A." Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
52 results on '"Ducassou, A."'

Search Results

1. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

2. ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

3. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

4. Antinuclear antibody–associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus

6. The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study

7. The uterine volume is dramatically decreased after hematopoietic stem cell transplantation during childhood regardless of the conditioning regimen

8. PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study

9. Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias

10. Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study

11. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety

12. Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation

13. Should We Consider Para-Aortic Lymphadenectomy For Stage IIIC1 Cervical Cancer ? The PAROLA Phase III Trial: A GINECO, ENGOT, And GCIG Study

14. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

15. Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes

18. Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

22. Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

23. Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL

24. NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

25. Chronic Graft-Versus-Host Disease in Long-Term Survivors of Childhood Leukemia

26. ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

28. Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group

29. Late Effects in Survivors of Infantile Acute Leukemia Are Less Severe Than Expected: A Study of the L.E.a Program

30. Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial

31. Metabolic Syndrome in Long-Term Survivors of Childhood Acute Leukemia Treated without Hematopoietic Stem Cell Transplantation: An L.E.Α. Study

32. Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)

33. Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)

34. Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)

35. Relevance of a One-Year Maintenance Therapy with Interleukin-2 in the Treatment of Childhood Acute Myeloid Leukemia: Results from the French Multicenter, Phase III, Randomized Controlled Sfce Trial, ELAM02

Catalog

Books, media, physical & digital resources